Thiogenesis Therapeutics (TSXV:TTI) Total Liabilities : C$0.11 Mil (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics Total Liabilities?

Thiogenesis Therapeutics's Total Liabilities for the quarter that ended in Sep. 2024 was C$0.11 Mil.

Thiogenesis Therapeutics's quarterly Total Liabilities declined from Mar. 2024 (C$0.35 Mil) to Jun. 2024 (C$0.31 Mil) and declined from Jun. 2024 (C$0.31 Mil) to Sep. 2024 (C$0.11 Mil).

Thiogenesis Therapeutics's annual Total Liabilities increased from Feb. 2021 (C$0.06 Mil) to Feb. 2022 (C$3.49 Mil) but then declined from Feb. 2022 (C$3.49 Mil) to Dec. 2023 (C$1.71 Mil).

Thiogenesis Therapeutics Total Liabilities Historical Data

The historical data trend for Thiogenesis Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thiogenesis Therapeutics Total Liabilities Chart

Thiogenesis Therapeutics Annual Data

Trend

Dec19

Dec20

Feb21

Feb22

Dec23

Total Liabilities

0.01

0.36

0.06

3.49

1.71

Thiogenesis Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial											0.32	1.71	0.35	0.31	0.11

Thiogenesis Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Thiogenesis Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.713	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1.71

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	7.243	-	5.53
	=	1.71

Thiogenesis Therapeutics's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.106	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	0.11

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	4.254	-	4.148
	=	0.11

Thiogenesis Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Thiogenesis Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Thiogenesis Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

TTIPF:USA Q8M:Germany

Address

4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6

Website

https://www.thiogenesis.com

Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.

Executives

Vincent P. Stanton

10% Security Holder